Quarterly ResultApr 30, 2026, 04:31 PM
EBS Q1 Revenue $156.1M (-30%); Net Income $6.8M (-90%)
AI Summary
Emergent BioSolutions Inc. reported Q1 2026 total revenues of $156.1 million, a 30% decrease year-over-year, and net income of $6.8 million, down 90%. Despite the significant financial declines, the company highlighted a strong start to 2026 with revenues above guidance and strengthened financial position through debt refinancing. Key business updates include new manufacturing partnerships, expansion of NARCAN® initiatives, securing substantial government contracts for medical countermeasures, and a share repurchase authorization.
Key Highlights
- Total Revenues for Q1 2026 were $156.1 million, a 30% decrease from Q1 2025.
- Net Income for Q1 2026 was $6.8 million, a 90% decrease from Q1 2025.
- Adjusted EBITDA for Q1 2026 was $35.6 million, a 55% decrease from Q1 2025.
- Secured new strategic manufacturing partnerships with SAB Biotherapeutics and Substipharm Biologics.
- Refinanced term loan with a new $150 million facility and amended asset-backed loan facility.
- Board authorized up to $50.0 million in share repurchases through March 31, 2027.
- Secured over $60 million in new contract awards for smallpox medical countermeasures and $140 million with Canada.
- Naloxone product sales decreased 5% to $42.9 million; Anthrax MCM sales decreased 55% to $21.6 million.